Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Jarrod Longcor: ESMO highlights

Jarrod Longcor • 28 Sep 2019
ESMO 2019
General

Jarrod Longcor, MA, MBA, Cellectar Biosciences, Madison, WI, gives his ESMO 2019 highlights, specifically mentioning tyrosine kinase inhibitors and how their use is evolving, immunotherapies and where there are current gabs in research. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Jarrod Longcor

R/R DLBCL challanges: novel therapeutics 1:15
R/R DLBCL challanges: novel therapeutics
Jarrod Longcor • 28 Sep 2019
Phospholipid drug conjugate therapies 1:08
Phospholipid drug conjugate therapies
Jarrod Longcor • 28 Sep 2019

Related Videos

Opportunities and challenges for real-time AI decision support in transplant care 4:47
Opportunities and challenges for real-time AI decision support in transplant care
Amin Turki • 5 Sep 2025
How AI and digital innovation are transforming transplant care 4:02
How AI and digital innovation are transforming transplant care
Amin Turki • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Stem cell transplant in 2025: latest advances, improving GvHD, and key clinical trials 8:12
Stem cell transplant in 2025: latest advances, improving GvHD, and key clinical trials
Alexandra Gomez-Arteaga • 10 Sep 2025
The content of VJHemOnc is intended for healthcare professionals